Search

A study conducted by researchers at the General Hospital of Ningxia Medical University has investigated the role of SPRY4 intronic transcript 1 (SPRY4-IT1) in gastrointestinal stromal tumors (GIST). The study found that SPRY4-IT1, a long non-coding RNA, is highly expressed in GIST and enhances the activation and expression of KIT, a proto-oncogene. This leads to increased cell survival, proliferation, and resistance to imatinib, a targeted therapeutic drug for GIST. The findings provide new insights into the regulation of KIT signaling and the resistance of GIST to targeted therapy. [Extracted from the article]

A report from the Knight Cancer Institute in Portland, Oregon discusses the use of adjuvant imatinib therapy in patients with high-risk resected gastrointestinal stromal tumors (GIST). The study found that while adjuvant imatinib therapy improved recurrence-free survival (RFS), it did not have a clear impact on ultimate recurrence, overall survival (OS), or time to imatinib resistance (TTIR). The researchers suggest that additional studies are needed to determine the benefit of adjuvant therapy versus initiating therapy at first radiographic recurrence. This research has been peer-reviewed and published in the Journal of Surgical Oncology. [Extracted from the article]

A recent study conducted by researchers at the University of Bologna in Italy has explored potential novel treatments for gastrointestinal stromal tumors (GISTs). The study focused on the hydroalcoholic extract from the leaves of Arbutus unedo L. (AUN) and its chemotherapeutic properties. The researchers found that a subfraction of AUN, called FR2-A, affected the viability of both imatinib-sensitive and -resistant GIST cells. Further analysis revealed that pyrogallol-bearing compounds were the main components of the active subfractions. Although the mechanism of action was non-specific, the established subfractions showed promising chemotherapeutic properties for GIST cells, including those that are imatinib-resistant. Further studies are needed to investigate the potential of pyrogallol-bearing compounds as an alternative treatment for GISTs. [Extracted from the article]

A recent study conducted at Oregon Health & Science University (OHSU) examined the relationship between kinase mutations and the response to imatinib therapy in patients with metastatic gastrointestinal stromal tumors (GISTs). The study found that activating mutations of KIT or PDGFRA were present in the majority of GISTs, and the mutational status of these oncoproteins was predictive of the clinical response to imatinib. Patients with GISTs harboring exon 11 KIT mutations had a higher response rate and longer survival compared to those with exon 9 KIT mutations or no detectable kinase mutation. PDGFRA mutations were also found to explain response and sensitivity to imatinib in some GISTs lacking KIT mutations. [Extracted from the article]

A recent study conducted by the Fred Hutchinson Cancer Research Center examined the treatment access and outcomes for patients with gastrointestinal stromal tumors (GIST) in low- and middle-income countries (LMICs). The study focused on patients who received tyrosine kinase inhibitors, specifically imatinib and sunitinib, through The Max Foundation programs. The findings revealed that the outcomes for patients in LMICs were similar to those in high-resource countries, highlighting the feasibility and relevance of administering oral anticancer therapy in LMICs. This study addresses a critical gap in cancer care and emphasizes the importance of providing access to effective treatments for GIST patients worldwide. [Extracted from the article]

A recent study conducted at the Affiliated Hospital of Qingdao University explores the tumor immune microenvironment of imatinib-resistant gastrointestinal stromal tumors (GIST) at the single-cell level. The researchers used single-cell RNA-sequencing to analyze the transcriptomic signatures of the tumor microenvironment (TME) in primary tumors, peritoneal metastases, and liver metastases of patients with locally advanced or advanced GIST. The study revealed unique tumor evolutionary patterns, transcriptome features, dynamic cell-state changes, and different metabolic reprogramming. The findings suggest that targeting Treg cells and IDO1+ dendritic cells may provide new therapeutic strategies for imatinib-resistant GIST. [Extracted from the article]

A recent study conducted at Weifang People's Hospital in Shandong, China, has explored the use of smart pH-sensitive Fe3O4/PEC/Imatinib nanoparticles as a targeted drug delivery system for gastric cancer treatment. The researchers synthesized these nanoparticles and characterized their structural features using various techniques. The results showed that the Imatinib-loaded modified PEC-magnetic nanoparticles had proper encapsulation and loading performance, and their drug release was sensitive to pH changes. The study concluded that the loading of Imatinib on the nanoparticles significantly improved the anticancer effect of the drug. [Extracted from the article]

Keywords: Antineoplastics; Asia; BCR-ABL Tyrosine Kinase Inhibitors; China; Clinical Research; Clinical Trials and Studies; Digestive System Diseases and Conditions; Digestive System Neoplasms; Drugs and Therapies; Gastroenterology; Gastrointestinal Diseases and Conditions; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Genetics; Health and Medicine; Imatinib Therapy; Multikinase Inhibitors; Pharmaceuticals; Protein Kinase Inhibitors; Sunitinib Therapy; Tyrosine Kinase Inhibitors; VEGF - VEGFR Inhibitors; VEGFR Inhibitors EN Antineoplastics Asia BCR-ABL Tyrosine Kinase Inhibitors China Clinical Research Clinical Trials and Studies Digestive System Diseases and Conditions Digestive System Neoplasms Drugs and Therapies Gastroenterology Gastrointestinal Diseases and Conditions Gastrointestinal Neoplasms Gastrointestinal Stromal Tumors Genetics Health and Medicine Imatinib Therapy Multikinase Inhibitors Pharmaceuticals Protein Kinase Inhibitors Sunitinib Therapy Tyrosine Kinase Inhibitors VEGF - VEGFR Inhibitors VEGFR Inhibitors 1820 1820 1 11/06/23 20231106 NES 231106 2023 NOV 6 (NewsRx) -- By a News Reporter-Staff News Editor at Gastroenterology Week -- A new study on gastrointestinal stromal tumors is now available. Fewer Grade 3/4 treatment-related TEAEs were reported with ripretinib than with sunitinib (16.7% vs 55.6%), as were treatment-related TEAEs leading to dose interruption (7.4% vs 42.6%), dose reduction (20.4% vs 29.6%) and treatment discontinuation (1.9% vs 7.4%).". [Extracted from the article]

Keywords: Antineoplastics; BCR-ABL Tyrosine Kinase Inhibitors; Digestive System Diseases and Conditions; Digestive System Neoplasms; Drugs and Therapies; Gastroenterology; Health and Medicine; Imatinib Therapy; Pharmaceuticals; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors EN Antineoplastics BCR-ABL Tyrosine Kinase Inhibitors Digestive System Diseases and Conditions Digestive System Neoplasms Drugs and Therapies Gastroenterology Health and Medicine Imatinib Therapy Pharmaceuticals Protein Kinase Inhibitors Tyrosine Kinase Inhibitors 459 459 1 08/28/23 20230901 NES 230901 2023 SEP 1 (NewsRx) -- By a News Reporter-Staff News Editor at Gastroenterology Week -- Investigators publish new report on digestive system neoplasms. Antineoplastics, BCR-ABL Tyrosine Kinase Inhibitors, Digestive System Diseases and Conditions, Digestive System Neoplasms, Drugs and Therapies, Gastroenterology, Health and Medicine, Imatinib Therapy, Pharmaceuticals, Protein Kinase Inhibitors, Tyrosine Kinase Inhibitors. [Extracted from the article]

Antineoplastics, BCR-ABL Tyrosine Kinase Inhibitors, Digestive System Diseases and Conditions, Digestive System Neoplasms, Drugs and Therapies, Gastroenterology, Gastrointestinal Diseases and Conditions, Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors, Health and Medicine, Imatinib Therapy, Pharmaceuticals, Protein Kinase Inhibitors, Surgery, Tyrosine Kinase Inhibitors Keywords: Antineoplastics; BCR-ABL Tyrosine Kinase Inhibitors; Digestive System Diseases and Conditions; Digestive System Neoplasms; Drugs and Therapies; Gastroenterology; Gastrointestinal Diseases and Conditions; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Health and Medicine; Imatinib Therapy; Pharmaceuticals; Protein Kinase Inhibitors; Surgery; Tyrosine Kinase Inhibitors EN Antineoplastics BCR-ABL Tyrosine Kinase Inhibitors Digestive System Diseases and Conditions Digestive System Neoplasms Drugs and Therapies Gastroenterology Gastrointestinal Diseases and Conditions Gastrointestinal Neoplasms Gastrointestinal Stromal Tumors Health and Medicine Imatinib Therapy Pharmaceuticals Protein Kinase Inhibitors Surgery Tyrosine Kinase Inhibitors 1057 1057 1 07/24/23 20230725 NES 230725 2023 JUL 28 (NewsRx) -- By a News Reporter-Staff News Editor at Gastroenterology Week -- Research findings on digestive system neoplasms are discussed in a new report. [Extracted from the article]

Keywords: Tehran; Iran; Antineoplastics; BCR-ABL Tyrosine Kinase Inhibitors; Collagen; Drugs and Therapies; Extracellular Matrix Proteins; Gastroenterology; Health and Medicine; Imatinib Therapy; Liver Cirrhosis; Liver Diseases and Conditions; Liver Fibrosis; Pharmaceuticals; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors EN Tehran Iran Antineoplastics BCR-ABL Tyrosine Kinase Inhibitors Collagen Drugs and Therapies Extracellular Matrix Proteins Gastroenterology Health and Medicine Imatinib Therapy Liver Cirrhosis Liver Diseases and Conditions Liver Fibrosis Pharmaceuticals Protein Kinase Inhibitors Tyrosine Kinase Inhibitors 910 910 1 07/24/23 20230725 NES 230725 2023 JUL 28 (NewsRx) -- By a News Reporter-Staff News Editor at Gastroenterology Week -- Research findings on Liver Diseases and Conditions - Liver Fibrosis are discussed in a new report. Tehran, Iran, Antineoplastics, BCR-ABL Tyrosine Kinase Inhibitors, Collagen, Drugs and Therapies, Extracellular Matrix Proteins, Gastroenterology, Health and Medicine, Imatinib Therapy, Liver Cirrhosis, Liver Diseases and Conditions, Liver Fibrosis, Pharmaceuticals, Protein Kinase Inhibitors, Tyrosine Kinase Inhibitors. [Extracted from the article]

In this exploratory study we aimed to determine the correlation between plasma and tumour imatinib concentrations in the neoadjuvant setting, investigate tumour imatinib distribution patterns within GISTs, and analyse its correlation with pathological response. Keywords: Antineoplastics; BCR-ABL Tyrosine Kinase Inhibitors; Drugs and Therapies; Gastroenterology; Health and Medicine; Imatinib Therapy; Pharmaceuticals; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors EN Antineoplastics BCR-ABL Tyrosine Kinase Inhibitors Drugs and Therapies Gastroenterology Health and Medicine Imatinib Therapy Pharmaceuticals Protein Kinase Inhibitors Tyrosine Kinase Inhibitors 1575 1575 1 06/12/23 20230612 NES 230612 2023 JUN 16 (NewsRx) -- By a News Reporter-Staff News Editor at Gastroenterology Week -- Data detailed on BCR-ABL tyrosine kinase inhibitors have been presented. [Extracted from the article]